miRNA Targeting Angiogenesis as a Potential Therapeutic Approach in the Treatment of Colorectal Cancers

Author(s): Forouzan Amerizadeh, Majid Khazaei, Mona Maftouh, Ramin Mardani, Afsane Bahrami*

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 39 , 2018

Become EABM
Become Reviewer
Call for Editor


Angiogenesis refers to the formation of recent blood vessels, which is one of the characteristics of cancer progression and it has been deliberated as a putative target to the treatment of many kinds of cancers. The VEGF signaling substrate is very important for angiogenesis and is commonly high-regulated in tumors. As a result, this molecule has attracted the attention of most of the researchers to develop antiangiogenic therapies. We have presented that VEGF blockage in neoadjuvant setting via bevacizumab, aflibercept and sunitinib not only has revealed some promising benefits but also has shown a large negative outcome in the adjuvant trials. However, at an advanced stage of tumors, suppression of VEGF alone is inadequate to stop advancement, encouraging drug resistance, and probably enhancing metastasis and invasion in the tumor microenvironment, thereby suggesting the therapeutic potential of targeting angiogenic pathways in gastrointestinal cancers.

Keywords: angiogenesis, vascular endothelial growth factor, bevacizumab, blood vessels, cancers, antiangiogenic therapies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 10 January, 2019
Page: [4668 - 4674]
Pages: 7
DOI: 10.2174/1381612825666190110161843
Price: $65

Article Metrics

PDF: 24
PRC: 1